Easton Capital
Easton Capital is a venture capital firm focused on healthcare and life sciences. The firm emphasizes capital-efficient investments that address fundamental unmet medical needs and typically finances companies that require limited additional capital to reach market or become acquisition targets. Easton manages approximately $200 million across several funds and targets investments that it can lead or co-lead while providing financial, strategic and operational support to portfolio companies. (Sources: http://www.eastoncapital.com/overview.html, http://www.eastoncapital.com/index.html)
Easton Capital
New York, New York, United States, North America
Services
Equity funding (lead or co-lead)
Provides venture equity investments, typically leading or co-leading rounds and participating in follow-on financings through strategic co-investment relationships with institutional investors.
Strategic and operational guidance
Provides portfolio companies with strategic, operational and commercialization guidance leveraging the firm’s industry experience across science, clinical affairs, operations and business development.
Healthcare industry relationships and partnership facilitation
Assists portfolio companies in developing relationships with large pharmaceutical and strategic partners, and in structuring transactions that can lead to strategic acquisitions or licensing.
Sector-specific commercial and IP support
Offers commercialization, clinical development and intellectual property guidance tailored to therapeutics, devices, diagnostics and healthcare IT companies.
Equity funding (lead or co-lead)
Provides venture equity investments, typically leading or co-leading rounds and participating in follow-on financings through strategic co-investment relationships with institutional investors.
Strategic and operational guidance
Provides portfolio companies with strategic, operational and commercialization guidance leveraging the firm’s industry experience across science, clinical affairs, operations and business development.
Healthcare industry relationships and partnership facilitation
Assists portfolio companies in developing relationships with large pharmaceutical and strategic partners, and in structuring transactions that can lead to strategic acquisitions or licensing.
Sector-specific commercial and IP support
Offers commercialization, clinical development and intellectual property guidance tailored to therapeutics, devices, diagnostics and healthcare IT companies.
Portfolio
Lead asset PRM-151 in Phase 2 for IPF and myelofibrosis; Bristol-Myers Squibb obtained an exclusive right to acquire Promedior under an agreement with potential aggregate payments up to $1.25 billion (announced Aug 31, 2015).
#Therapeutics
Described on the site as a portfolio company developing gene therapy approaches for genetic blood disorders.
#Therapeutics (gene therapy)
Described as a system to reduce medication dispensing mistakes.
#Healthcare IT / patient safety
Included as a case study and listed under Healthcare IT portfolio.
#Healthcare IT / communications
Lead asset PRM-151 in Phase 2 for IPF and myelofibrosis; Bristol-Myers Squibb obtained an exclusive right to acquire Promedior under an agreement with potential aggregate payments up to $1.25 billion (announced Aug 31, 2015).
#Therapeutics
Described on the site as a portfolio company developing gene therapy approaches for genetic blood disorders.
#Therapeutics (gene therapy)
Described as a system to reduce medication dispensing mistakes.
#Healthcare IT / patient safety
Included as a case study and listed under Healthcare IT portfolio.
#Healthcare IT / communications